Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamorolone phase IIb trial in ambulant boys with Duchenne muscular dystrophy
NL-OMON50318Phase 2Active, not recruiting
- Sponsor
- ReveraGen BioPharma
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vamorolone in Duchenne muscular dystrophy (DMD) (4 arms), sponsored by ReveraGen BioPharma. Primary endpoints: Premature discontinuation due to adverse events and Time to Stand Test velocity. Started Dec 2019; status: active, not recruiting.
02
Drugs
vamorolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON50318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50318.